Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Newcastle Disease
Research reports on Newcastle disease from C. Pfirschke and colleagues provide new insights
June 3rd, 2009
According to a study from Heidelberg, Germany, "Oncolytic virotherapy, a new type of cancer therapy involving viruses with oncolytic and immunostimulatory potential, is based on tumor selective viral replication, resulting in a specific lysis Of tumor cells. Effective tumor targeting of oncolytic viruses remains a major problem because only a fraction of systemically applied viruses can reach the tumor tissue." "We describe for the first time in an in vitro CO-Culture system that T lymphocytes can be loaded with Newcastle disease virus (NDV) in such a way that the virus load will be transferred to the tumor target Cells upon contact of the T cells with tumor cells. The...
Source: Vaccine Weekly (2009-06-03)
|
